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Treating ROP: how and when
Laser treatment of 
ROP is highly effective. 
However, special care 
should be taken when 
treating preterm or 
newborn infants, and 
long-term follow-up is 
essential. There are also 
new treatments on the 
horizon, particularly 
in cases where laser 
treatment is not possible 
or has failed.
Indications for treatment
The Early Treatment of Retinopathy (ROP) trial 
(ET-ROP)1 clearly showed that earlier laser treatment 
gives better results than waiting until 'threshold 
disease' develops. The ET-ROP indications for 
treatment use a combination of zone, stage and 
whether plus disease or aggressive posterior ROP is 
present (Figure 4, pp. 58). 
ROP in zone I has the worst prognosis and so requires 
treatment at an earlier stage than ROP in zone II or III. 
The presence of plus disease also indicates a poorer 
prognosis. Eyes with plus disease and aggressive 
posterior ROP also have a poorer prognosis.
Laser treatment
The mainstay of treatment for severe ROP is peripheral 
retinal photocoagulation, delivered by laser. Only the 
avascular retinal periphery should be treated. The laser 
burns should be light and almost confluent (Figure 1). 
Laser treatment requires a trained and highly skilled 
ophthalmologist.
Treatment is painful and should be given under topical 
anaesthesia with or without sedation, or under general 
anaesthesia. It is essential that the infant is monitored 
closely during treatment. A neonatologist or trained 
neonatal nurse must be present.
Babies should be followed up closely after treatment 
(after 1 week initially) to ensure that the ROP is 
regressing and that treatment of the peripheral retina is 
complete, with no skip areas (areas of untreated retina). 
Further treatment should be given if the ROP is not 
regressing, including to skip areas.
Other treatment
Agents which block vascular endothelial growth factor 
(VEGF), which stimulates new vessel growth, are being 
explored as a treatment for ROP.2 Although these 
agents, which are given by intravitreal injection, can 
give rapid short-term resolution of ROP, there are 
concerns about the long-term complications in the 
eye and possible systemic complications. For this 
reason, anti-VEGF agents are only recommended when 
laser treatment is not possible (i.e., the baby is too 
sick, the pupils do not dilate, or there is intravitreal 
haemorrhage) or when extensive laser treatment has 
failed. Parents should be fully informed about the risks 
before treatment and must give their consent.
Follow-up after treatment
All babies treated for ROP should have long-term 
follow-up visits to detect and manage the eye conditions 
which frequently develop in these children (pp. 62–64). 
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Figure 1 Photocoagulation pattern for ROP. The burns 
should be almost confluent. 
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Ophthalmologist checks whether ROP treatment has been successful. INDIA
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